Neumora Therapeutics, Inc. SEC filings NMRA
Neumora Therapeutics, Inc. has 258 filings in SEC EDGAR's recent list, going back to Nov 8, 2021. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (listing notice). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-K | Annual report | Mar 30, 2026 | Dec 31, 2025 |
| 10-K | Annual report | Mar 3, 2025 | Dec 31, 2024 |
| 10-K | Annual report | Mar 7, 2024 | Dec 31, 2023 |
Showing 3 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- NMRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Watertown, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1885522
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.